Mutant MMLV Reverse Transcriptase for GC-Rich cDNA Synthesis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Reverse transcriptases face challenges in synthesizing full-length cDNA from RNA templates with high GC content due to RNA secondary structure, leading to truncated products and reduced fidelity, especially at elevated temperatures, which compromises enzyme activity and integrity of the RNA.

Innovation Solution

A mutant Moloney murine leukemia virus (MMLV) reverse transcriptase with specific amino acid substitutions and a truncated N-terminus, optimized for higher temperatures, enhances the production of full-length cDNA from GC-rich templates by improving enzyme efficiency and fidelity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If the reaction temperature is elevated to avoid RNA secondary structure formation, then reverse transcriptase fidelity and cDNA length are improved, but RNA integrity is compromised due to reduced enzyme activity

Engineering Contradiction:
ImprovecDNA fidelityVSAvoidRNA integrity
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The patent applies parameter changes by modifying the reaction temperature to 50°C, which optimizes the balance between avoiding RNA secondary structure formation (improving fidelity) and maintaining sufficient enzyme activity (preserving RNA integrity). This temperature parameter was specifically selected to resolve the contradiction between these two requirements.

Inventive Principle:
Principle #35Parameter changes

2Manufacturing precision

If the reaction temperature is elevated to prevent RNA secondary structure, then full-length cDNA production is improved, but enzyme activity is reduced

Engineering Contradiction:
ImprovecDNA lengthVSAvoidenzyme activity
Core Design Contradiction:
Manufacturing precisionVSPower

Solution Approach 1:

The patent resolves this contradiction by optimizing the reaction temperature parameter to 50°C and extending the incubation time to 2 hours. This parameter combination allows sufficient time for the enzyme to synthesize full-length cDNA at the moderate temperature, balancing thermal denaturation of secondary structures with maintenance of enzyme activity.

Inventive Principle:
Principle #35Parameter changes

3Manufacturing precision

If standard MMLV reverse transcriptase is used at elevated temperatures, then non-specific priming is reduced, but enzyme activity and cDNA synthesis efficiency are compromised

Engineering Contradiction:
Improvepriming specificityVSAvoidcDNA synthesis efficiency
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies parameter changes by setting the reaction temperature to 50°C and incubation time to 2 hours, which optimizes both priming specificity and synthesis efficiency. This temperature is high enough to reduce non-specific priming but combined with extended time to maintain adequate enzyme activity for efficient cDNA synthesis.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs preliminary action by performing a reverse transcription reaction optimized for high fidelity and full-length coverage before proceeding to PCR amplification. This preliminary optimization ensures that the cDNA template quality is maximized before the amplification step, improving overall workflow efficiency.

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The mutant MMLV reverse transcriptase achieves a higher proportion of full-length cDNA molecules compared to commercial variants like SuperScript IV and ProtoScript II, particularly at temperatures above 42°C, demonstrating improved performance in library synthesis and NextGen sequencing.

Implementation Method 1

reverse transcriptases were first identified in RNA viruses. Subsequently, reverse transcriptases were isolated and purified directly from virus particles, cells or tissues. More recently, mutants and fusion proteins have been created in the quest for improved properties such as thermostability, fidelity and activity.

Methodology Applied
Scientific EffectReverse transcription:

Implementation Method 2

Reverse transcriptases are multi-functional enzymes with three enzymatic activities including RNA- and DNA-dependent DNA polymerization activity, and an RNaseH activity that catalyzes the cleavage of RNA in RNA-DNA hybrids.

Methodology Applied
Scientific EffectRNaseH activity: Hydrolysis

Implementation Method 3

Copying RNA can be inhibited by the presence of RNA secondary structure which can stall cDNA synthesis resulting in truncated cDNA molecules. The formation of secondary structure can be avoided at higher temperature.

Methodology Applied
Scientific EffectThermal denaturation: Heating

Data Source

PatentEP3516050B1A mutant reverse transcriptase
Publication Date: 2021.08.11 NEW ENGLAND BIOLABS INC
  • EP3516050B1 patent drawingFigure 1
  • EP3516050B1 patent drawingFigure 2
  • EP3516050B1 patent drawingFigure 3

AI summary

A mutant MMLV reverse transcriptase that may have an improvement in one or more properties is provided. For example, the present reverse transcriptase is believed to be more efficient relative to other commercially available MMLV reverse transcriptase variants, particularly for templates with a higher GC content.